

产品名称：丁苯那嗪

产品别名：Tetrabenazine

生物活性：					
Description	Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder. Target: Others tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders. In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia [1, 2]. Twenty patients with tardive dyskinesia (mean duration = 43.7 months) were videotaped before and after tetrabenazine treatment. One patient did not tolerate tetrabenazine owing to sedation. The remaining 19 were rated after a mean of 20.3 weeks at a mean tetrabenazine dose of 57.9 mg/day. There were significant improvements in mean scores on both the patient AIMS self-rating and the AIMS motor subset evaluated by the blind videotape raters. All 19 patients continued to take tetrabenazine after the study [3].				
Solvent&Solubility	In Vitro: DMSO : ≥ 3.2 mg/mL (10.08 mM) * " \geq " means soluble, but saturation unknown.				
		Solvent	Mass		
		Concentration	1 mg	5 mg	10 mg
	Preparing	1 mM	3.1504 mL	15.7520 mL	31.5040 mL
Stock Solutions	5 mM	0.6301 mL	3.1504 mL	6.3008 mL	
	10 mM	0.3150 mL	1.5752 mL	3.1504 mL	
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。					
References	[1]. Jankovic, J. and J. Beach, <u>Long-term effects of tetrabenazine in hyperkinetic movement disorders</u> . <u>Neurology</u> , 1997. 48(2): p. 358-62. [2]. Kenney, C., C. Hunter, and J. Jankovic, <u>Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders</u> . <u>Mov Disord</u> , 2007. 22(2): p. 193-7. [3]. Ondo, W.G., P.A. Hanna, and J. Jankovic, <u>Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol</u> . <u>Am J Psychiatry</u> , 1999. 156(8): p. 1279-81.				